The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a strategic review of the MedTech and Diagnostics sector, Evercore ISI has adjusted its price targets for key players in the diabetes care market. Analysts reduced the price target for Abbott Laboratories (ABT) to $112 from $120, and similarly lowered the target for Insulet (PODD) while maintaining an 'Outperform' rating. Despite the valuation adjustments, Insulet continues to demonstrate operational momentum, recently expanding its global footprint by launching the Omnipod 5 system in Spain, marking its 26th international market.
This recalibration reflects a broader sector outlook that balances steady medical procedure volumes against updated valuation metrics for 2026. In the competitive landscape, peer firm Dexcom (DXCM) recently reported a 24% year-over-year revenue increase in its latest quarterly results, according to financial reports, highlighting the robust demand in the continuous glucose monitoring space. Evercore's adjustment is viewed as a tactical alignment with current market multiples rather than a shift in fundamental confidence in the underlying technology.
Regarding market performance, ABT shares stood at $95.84 at close July 7, 2026, after fluctuating between a day high of $98.14 and a low of $95.74, per market data. Investors are now looking toward broader economic catalysts, including the upcoming U.S. Factory Orders report and employment data, which may influence sector rotation and risk appetite within healthcare and medical device equities in the coming sessions.